Abstract
The diagnosis of ABO hemolytic disease of the newborn (ABO HDN) has been the subject of considerable debate and clinical confusion. Its use as an overarching default diagnosis for hyperbilirubinemia in all ABO incompatible neonates regardless of serological findings is problematic and lacks diagnostic precision. Data on hemolysis indexed by carbon monoxide (CO) levels in expired air (ETCOc) and blood (COHbc) support an essential role for a positive direct antiglobulin test (DAT) in making a more precise diagnosis of ABO HDN. A working definition that includes ABO incompatibility, significant neonatal hyperbilirubinemia, and a positive DAT is needed to gain clarity and consistency in the diagnosis of ABO HDN. Absent a positive DAT, the diagnosis of ABO HDN is suspect. Instead, a negative DAT in a severely hyperbilirubinemic ABO incompatible neonate should trigger an exhaustive search for an alternative cause, a search that may require the use of targeted gene panels.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Halbrecht I. Role of hemoagglutinins anti-A and anti-B in pathogenesis of jaundice of the newborn (icterus neonatorum precox). Am J Dis Child. 1944;68:248–49.
Zuelzer WW, Cohen F. ABO hemolytic disease and heterospecific pregnancy. Pediatr Clin North Am. 1957;4:405–28.
Krog GR, Lorenzen H, Clausen FB, Hansen AT, Donneborg ML, Dziegiel MH. ABO haemolytic disease of the newborn: Improved prediction by novel integration of causative and protective factors in newborn and mother. Vox Sang. 2022;117:415–23.
Routray SS, Behera R, Mallick B, Acharya D, Sahoo JP, Kanungo GN, et al. The spectrum of hemolytic disease of the newborn: Evaluating the etiology of unconjugated hyperbilirubinemia among neonates pertinent to immunohematological workup. Cureus. 2021;13:e16940.
van der Geest BAM, Rosman AN, Bergman KA, Smit BJ, Dijk PH, Been JV, et al. Severe neonatal hyperbilirubinaemia: lessons learnt from a national perinatal audit. Arch Dis Child Fetal Neonatal Ed. 2022;107:527–32.
Kemper AR, Newman TB, Slaughter JL, Maisels MJ, Watchko JF, Downs SM, et al. Clinical practice guideline revision: Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150:e2022058859.
Bhutani VK, Johnson LH, Maisels MJ, Newman TB, Phibbs C, Stark AR, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004;24:650–62.
Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot US Kernicterus Registry (1992–2004). J Perinatol. 2009;29:S25–45.
Christensen RD, Yaish HM, Gallagher PG. A pediatrician’s practical guide to diagnosing and treating hereditary spherocytosis in neonates. Pediatrics. 2015;135:1107–14.
Nieto JM, Rochas-Lopez S, Gonzalez-Fernandez FA, Villegas-Martinez A, Bolanos-Calderon E, Salido-Fierrez E, et al. Next generation sequencing for diagnosis of hereditary anemia: Experience in a Spanish reference center. Clin Chim Acta. 2022;531:112–9.
Steward SC, Chauvenet AR, O’Suoji C. Hereditary spherocytosis: Consequences of delayed diagnosis. SAGE Open Med. 2014;2:2050312114547093.
Ross ME, Emery SP, de Alarcon PA, Watchko JF. Hemolytic disease of the fetus and newborn. maternal antibody mediated hemolysis. In: Neonatal Hematology. Pathogenesis, Diagnosis, and Management of Hematologic Problems. 3rd Edition. PA de Alarcon, EJ Werner, RD Christensen, MC Sola-Visner (eds); Cambridge University Press, Cambridge, United Kingdom, 2021, p. 133–54.
Naiman JL. Erythroblastosis fetalis. In: Oski FA, Naiman JL (eds), Hematologic Problems of the Newborn (3rd Edition), WB Saunders, Philadelphia, 1982; pp. 283–346.
Zantek ND, Koepsell SA, Tharp DR Jr, Cohn CS. The direct antiglobulin test: a critical step in the evaluation of hemolysis. Am J Hematol. 2012;87:707–9.
Crowe EP, Goel R, Andrews J, Meyer EK, Wong TE, Sloan SR, et al. Survey of newborn direct antiglobulin testing practice in United States and Canadian transfusion services. Transfusion. 2021;61:1080–92.
Snyder EL, Falast GA. Significance of the direct antiglobulin test. Lab Med. 1985;16:89–96.
Klein HG, Anstee DJ. Hemolytic disease of the fetus and the newborn. In: Mollison’s Blood Transfusion in Clinical Medicine. 12th Edition. HG Klein, DJ Anstee (eds); John Wiley & Sons, Ltd. West Sussex, United Kingdom, 2014, p. 499–548.
Alter AA, Feldman F, Twersky J, De Vos E, Prutting DL, Miotti A, et al. Direct antiglobulin test in ABO hemolytic disease of the newborn. Obstet Gynecol. 1969;33:846–51.
Ozolek JA, Watchko JF, Mimouni F. Prevalence and lack of clinical significance of blood group incompatibility in mothers with blood type A or B. J Pediatr. 1994;125:87–91.
Herschel M, Karrison T, Wen M, Caldarelli L, Baron B. Isoimmunization is unlikely to be the cause of hemolysis in ABO-incompatible but direct antiglobulin test-negative neonates. Pediatrics. 2002;110:127–30.
Kaplan MJ, Hammerman C, Vreman HJ, Wong RJ, Stevenson DK. Hemolysis and hyperbilirubinemia in antiglobulin positive direct ABO group heterospecific neonates. J Pediatr. 2010;157:772–7.
Stevenson DK, Vreman HJ, Oh W, Fanaroff AA, Wright LL, Lemons JA, et al. Bilirubin production in healthy term infants as measured by carbon monoxide in breath. Clin Chem. 1994;40:1934–9.
Stevenson DK, Vreman HJ, Wong RJ. Bilirubin production and its measurement. In: Stevenson DK, Maisels MJ, Watchko JF, editors. Care of the Jaundiced Neonate. New York: McGraw Hill; 2012, p. 29–39.
Christensen RD, Lambert DK, Henry E, Yaish HM, Prchal JT. End-tidal carbon monoxide as an indicator of the hemolytic rate. Blood Cells Mol Dis. 2015;54:292–6.
Christensen RD, Malleske DT, Lambert DK, Baer VL, Prchal JT, Denson LE, et al. Measuring end-tidal carbon monoxide of jaundiced neonates in the birth hospital to identify those with hemolysis. Neonatology. 2016;109:1–5.
Bhutani VK, Maisels MJ, Schutzman DL, Castillo Cuadrado ME, Aby JL, Bogen DL, et al. Identification of risk for neonatal hemolysis. Acta Paediatr. 2018;107:1350–6.
Kaplan M, Muraca M, Hammerman C, Rubaltelli FF, Vilei MT, Vreman HJ, et al. Imbalance between production and conjugation of bilirubin: a fundamental concept in the mechanism of neonatal jaundice. Pediatrics. 2002;110:e47.
Schutzman DL, Gatien E, Ajayi S, Wong RJ. Carboxyhemoglobin levels as a predictor of risk for significant hyperbilirubinemia in African-American DAT+ infants. J Perinatol. 2016;36:386–88.
Kaplan M, Hammerman C, Vreman HJ, Wong RJ, Stevenson DK. Direct antiglobulin titer strength and hyperbilirubinemia. Pediatrics. 2014;134:e1340–e1344.
Elsaie AL, Taleb M, Nicosia A, Zangaladze A, Pease ME, Newton K, et al. Comparison of end-tidal carbon monoxide measurements with direct antiglobulin tests in the management of neonatal hyperbilirubinemia. J Perinatol. 2020;40:1513–17.
Hansen TWR, Bratlid D. Physiology of neonatal unconjugated hyperbilirubinemia. In: Stevenson DK, Maisels MJ, Watchko JF, editors. Care of the Jaundiced Neonate. New York: McGraw Hill; 2012, p. 65–95.
Voak D, Bowley CC. A detailed serological study on the prediction and diagnosis of ABO haemolytic disease of the newborn (ABO HD). Vox Sang. 1969;17:321–48.
Procianoy RS, Giacomini CB, Farina DM, Mollin GA, Winckler MI, Silveira MB, et al. Early diagnosis of ABO haemolytic disease of the newborn. Eur J Pediatr. 1987;146:390–93.
Romano EL, Hughes-Jones NC, Mollison PL. Direct antiglobulin reaction in ABO-haemolytic disease of the newborn. Br Med J. 1973;1:524–26.
Burkart P, Rosenfeld RE, Hsu TC, Wong KY, Nusbacher J, Shaikh SH, et al. Instrumented PVP-augmented antiglobulin tests. I. Detection of allogeneic antibodies coating otherwise normal erythrocytes. Vox Sang. 1974;26:289–304.
Klein HG, Anstee DJ. Blood grouping techniques. In: Mollison’s Blood Transfusion in Clinical Medicine. 12th Edition. HG Klein, DJ Anstee (eds); John Wiley & Sons, Ltd. West Sussex, United Kingdom, 2014, p. 303–55.
Merry AH, Thomson EE, Rawlinson VI, Stratton F. Quantitation of IgG on erythrocytes: correlation of number of IgG molecules per cell with the strength of the direct and indirect antiglobulin tests. Vox Sang. 1984;47:73–81.
Bakkeheim E, Bergerud U, Schmidt-Melbye AC, Akkök CA, Knut L, Fugelseth D, et al. Maternal IgG anti-A and anti-B titres predict outcome in ABO incompatibility in the neonate. Acta Paediatr. 2009;98:1896–901.
Mollison PL, Crome P, Hughes-Jones NC, Rochna E. Rate of removal from the circulation of red cells sensitized with different amounts of antibody. Br J Haematol. 1965;11:461–70.
Klein HG, Anstee DJ. Red cell incompatibility in vivo. In: Mollison’s Blood Transfusion in Clinical Medicine. 12th Edition. HG Klein, DJ Anstee (eds): John Wiley & Sons, Ltd. West Sussex, United Kingdom, 2014; p. 411–57.
Bhutani V, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999;103:6–14.
Matteocci A, De Rosa A, Buffone E, Pierelli L. Retrospective analysis of HDFN due to ABO incompatibility in a single institution over 6 years. Transfus Med. 2019;29:197–201.
Alter AA, Prutting DL, Hertz S, Bryan DE. Serologic specificity of the positive direct antiglobulin test in ABO heterospecific pregnancies. Obstet Gynecol. 1969;34:102–5.
Kumar R, Saini N, Kaur P, Sood T, Kaur G, Bedi RK, et al. Severe ABO hemolytic disease of the newborn with high maternal antibody titers in direct antiglobulin test negative neonate. Indian J Pediatr. 2016;83:740–1.
van Rossum HH, de Kraa N, Thomas M, Holleboom CAG, Castel A, van Rossum AP. Comparison of the direct antiglobulin test and the eluate technique for diagnosing haemolytic disease of the newborn. Practical Lab Med. 2015;3:17–22.
Desjardins L, Blajchman MA, Chintu C, Gent M, Zipursky A. The spectrum of ABO hemolytic disease of the newborn infant. J Pediatr. 1979;95:447–9.
Hsu TCS, Rosenfield RE, Rubinstein P. Instrumented PVP-augmented antiglobulin tests. III. IgG-coated cells in ABO incompatible babies; depressed hemoglobin levels in type A babies of Type O mothers. Vox Sang. 1974;26:326–33.
Ukita M, Takahashi A, Nunotani T, Kihana T, Watanabe S, Yamada N. IgG subclasses of anti-A and anti-B antibodies bound to the cord red cells of ABO incompatible pregnancies. Vox Sang. 1989;56:181–86.
Eder AF. Update on HDFN: new information on long-standing controversies. Immunohematology. 2006;22:188–95.
Christensen RD, Baer VL, MacQueen BC, O’Brien EA, Ilstrup SJ. ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program. J Perinatol. 2018;38:517–25.
Osborn LM, Lenarsky C, Oakes RC, Reiff MI. Phototherapy in full-term infants with hemolytic disease secondary to ABO incompatibility. Pediatrics. 1984;74:371–4.
Kaplan M, Hammerman C, Renbaum P, Klein G, Levy-Lahad E. Gilbert’s syndrome and hyperbilirubinemia in ABO-incompatible neonates. Lancet. 2000;356:652–53.
Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N. Engl J Med. 1995;333:1171–75.
Watchko JF. Review of the contribution of genetic factors to hyperbilirubinemia and kernicterus risk in neonates: a targeted update. Pediatr Med. 2021;4:17.
Watchko JF, Lin Z. Genetics of neonatal jaundice. In: Stevenson DK, Maisels MJ, and Watchko JF, editors. Care of the Jaundiced Neonate. New York: McGraw Hill; 2012, p. 1–27.
Petersen JP, Henricksen TB, Hollegaard MV, Vandborg PK, Hougaard DM, Thorlacius-Ussing O, et al. Extreme neonatal hyperbilirubinemia and a specific genotype: a population-based case-control study. Pediatrics. 2014;134:510–5.
Long J, Zhang S, Fang X, Luo Y, Liu J. Association of neonatal hyperbilirubinemia with uridine diphosphate-glucuronosyltransferase 1A1 gene polymorphisms: Meta-analysis. Pediatr Int. 2011;53:530–40.
Watchko JF, Lin Z, Clark RH, Kelleher AS, Walker MW, Spitzer AR, et al. Complex multifactorial nature of significant hyperbilirubinemia in neonates. Pediatrics. 2009;124:e868–77.
Kaplan M, Renbaum P, Levy-Lahad E, Hammerman C, Lahad A, Beutler E. Gilbert syndrome and glucose-6-phosphate dehydrogenase deficiency: a dose dependent genetic interaction crucial to neonatal hyperbilirubinemia. Proc Natl Acad Sci USA. 1997;94:12128–32.
Halis H, Ergin H, Koseler A, Atalay O. The role of UGT1A1 promoter polymorphism and exon-1 mutations in neonatal jaundice. J Matern Fetal Neonatal Med. 2017;30:2658–64.
Yu Y, Du L, Chen A, Chen L. Study of Gilbert’s syndrome-associated UGT1A1 polymorphism in jaundiced neonates of ABO incompatibility hemolysis disease. Am J Perinatol. 2020;37:652–7.
Christensen RD, Nussenzveig RH, Yaish HM, Henry E, Eggert LD, Agarwal AM. Causes of hemolysis in neonates with extreme hyperbilirubinemia. J Perinatol. 2014;34:616–9.
Watchko JF. Common hematologic problems in the newborn nursery. Pediatr Clin N. Am. 2015;62:509–24.
Das S, Shastry S, Chakravarthy PK, Baliga PB. Clinical implication of immunohaematological tests in ABO haemolytic disease of newborn: revisiting an old disease. Transfus Med. 2021;31:30–35.
Odell GB. Neonatal Hyperbilirubinemia. Grune & Stratton, New York, NY, 1980; p. 55.
Roy NB, Wilson EA, Henderson S, Wray K, Babbs C, Okoli S, et al. A novel 33-gene targeted resequencing panel provides accurate, clinical-grade diagnosis and improves patient management for rare inherited anaemias. Br J Haematol. 2016;175:318–30.
Russo R, Andolfo I, Manna F, Gambale A, Marra R, Rosato BE, et al. Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias. Am J Hematol. 2018;93:672–82.
Keir A, Apgalo M, Lieberman L, Callum J. How to use: the direct antiglobulin test in newborns. Arch Dis Child Educ Pr Ed. 2015;100:198–203.
Christensen RD, Agarwal AM, George TI, Bhutani VK, Yaish HM. Acute neonatal bilirubin encephalopathy in the State of Utah 2009-18. Blood Cells Mol Dis. 2018;72:10–13.
Rets A, Clayton AL, Christensen RD, Agarwal AM. Molecular diagnostic update in hereditary hemolytic anemia and neonatal hyperbilirubinemia. Int J Lab Hematol. 2019;41:95–101.
Christensen RD, Yaish HM. Hemolytic disorders causing severe neonatal hyperbilirubinemia. Clin Perinatol. 2015;42:515–27.
Acknowledgements
The author thanks Darrell Triulzi, M.D. for his insightful comments on an earlier draft of the paper.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Watchko, J.F. ABO hemolytic disease of the newborn: a need for clarity and consistency in diagnosis. J Perinatol 43, 242–247 (2023). https://doi.org/10.1038/s41372-022-01556-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41372-022-01556-6
This article is cited by
-
Effect of administration routes of oxytocin on hemoglobin in neonates with delayed umbilical cord clamping: a multi-centre randomized controlled clinical trial
Archives of Gynecology and Obstetrics (2024)
-
Alloimmune hemolytic disease of the fetus and newborn: genetics, structure, and function of the commonly involved erythrocyte antigens
Journal of Perinatology (2023)
-
A “Gold Standard” Test for Diagnosing and Quantifying Hemolysis in Neonates and Infants
Journal of Perinatology (2023)